Core Viewpoint - Jiangxi Tianxin Pharmaceutical Co., Ltd. reported a steady performance in the first half of 2025, with an increase in revenue and net profit, driven by its strong position in the vitamin industry and effective management strategies [1][2]. Company Overview and Financial Highlights - The company achieved an operating income of approximately 1.12 billion RMB, representing a 5.23% increase compared to the same period last year [2]. - The total profit reached approximately 424.59 million RMB, up by 3.54% year-on-year [2]. - The net profit attributable to shareholders was approximately 356.01 million RMB, reflecting a 3.14% increase from the previous year [2]. - The net cash flow from operating activities surged by 75.16%, primarily due to increased cash receipts from sales [2]. Business Operations - The company specializes in the research, production, and sales of single vitamins, focusing on B vitamins and other vitamin products, with a strong global market presence [6][7]. - The business is segmented into three main areas: B vitamins, other vitamins, and fine chemicals, with a diverse product portfolio [6][7]. - The company has established a robust supply chain and procurement strategy to ensure stable raw material supply and cost advantages [6][8]. Industry Position - The vitamin industry is characterized by stable demand, with growth driven by increasing global population and health awareness [6][7]. - China has become a major producer and exporter of vitamins, with the company holding a significant market share in various B vitamin products [6][7]. - The industry is undergoing consolidation, with leading manufacturers adjusting their operations to meet market demands, which is expected to improve profitability [6][7]. Competitive Advantages - The company has a comprehensive management and certification system, ensuring product quality and compliance with international standards [11][12]. - It maintains a strong focus on research and development, collaborating with academic institutions to enhance product offerings and production processes [11][12]. - The company emphasizes environmental protection and sustainability in its operations, aligning with regulatory requirements and market expectations [11][12].

证券代码：603235 证券简称：天新药业 公告编号：2025-031 江西天新药业股份有限公司 关于 2025 年第二季度经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所《上海证券交易所上市公司自律监管指引第 3 号——行 业信息披露》的相关规定，现将江西天新药业股份有限公司（以下简称"公司"） 2025 年第二季度经营数据（未经审计）公告如下： 一、 2025年第二季度主要经营数据 单位：元 币种：人民币 | 产品分类 | 2025 | 年 4-6 | 月收入 | 2024 | 年 4-6 | 月收入 | 同比变动 | | --- | --- | --- | --- | --- | --- | --- | --- | | 直销 | | 303,939,684.62 | | | 337,641,778.81 | | -9.98% | | 经销 | | 192,726,741.54 | | | 225,052,619.73 | | -14.36% | | 小计 | | 496,666,426. ...

证券代码：603235 证券简称：天新药业 公告编号：2025-021 江西天新药业股份有限公司 关于 2025 年第一季度经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所《上海证券交易所上市公司自律监管指引第 3 号——行 业信息披露》的相关规定，现将江西天新药业股份有限公司（以下简称"公司"） 2025 年第一季度经营数据（未经审计）公告如下： 一、 2025年第一季度主要经营数据 1、主营业务分产品情况 单位：元 币种：人民币 | 产品分类 | 2025 | 年 1-3 | 月收入 | 2024 | 年 1-3 月收入 | 同比变动 | | --- | --- | --- | --- | --- | --- | --- | | B 族维生素 | | 508,399,113.57 | | | 409,717,324.36 | 24.09% | | 其他维生素 | | 65,866,984.56 | | | 57,064,938.52 | 15.42% | | 精细化工品 | | 38,60 ...